13F HOLDINGS REPORT
SR ONE CAPITAL MANAGEMENT, LP
Quarter ended Q4 2025 · Filed February 12, 2026 · Accession 0001193125-26-048808
Total Value
$706.4M
Positions
13
Other Managers
0
Confidential Omitted
No
Holdings (13)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | Zenas BioPharma, Inc | ZBIO | 5,037,854 | $182.9M | 25.90% |
| 2 | Arcellx, Inc. | ACLX | 2,346,630 | $153.0M | 21.66% |
| 3 | CRISPR Therapeutics AG | CRSP | 2,038,763 | $106.9M | 15.14% |
| 4 | Design Therapeutics, Inc. | DSGN | 6,526,476 | $61.2M | 8.67% |
| 5 | Mineralys Therapeutics Inc. | MLYS | 1,563,966 | $56.8M | 8.03% |
| 6 | ARS Pharmaceuticals, Inc. | SPRY | 4,012,903 | $46.8M | 6.62% |
| 7 | ORIC Pharmaceuticals, Inc. | ORIC | 4,514,929 | $37.8M | 5.34% |
| 8 | Alumis Inc. | ALMS | 1,959,896 | $19.1M | 2.71% |
| 9 | Oruka Therapeutics, Inc | ORKA | 430,330 | $13.0M | 1.85% |
| 10 | Oculis Holding AG | OCSAW | 641,022 | $12.8M | 1.81% |
| 11 | enGene Holdings Inc. | ENGNW | 747,750 | $6.8M | 0.96% |
| 12 | Nkarta, Inc. | NKTX | 3,333,333 | $6.2M | 0.87% |
| 13 | Ultragenyx Pharmaceutical Inc. | RARE | 137,753 | $3.2M | 0.45% |